Grant and Funding Programs Offered by Research Alliance for Primary Immunodeficiency Discoveries (RAPID)
Overview of Available Grants and Funding
Research Alliance for Primary Immunodeficiency Discoveries (RAPID) is a Canadian registered charity funding research into Primary Immunodeficiency Disorders (PID) and rare genetic diseases. The organization supports gene therapy research, genetic testing, and mitochondrial health initiatives, primarily partnering with UCLA's gene therapy program. View Research Alliance for Primary Immunodeficiency Discoveries (RAPID)'s website for more information.
About Research Alliance for Primary Immunodeficiency Discoveries (RAPID)
What is the mission of Research Alliance for Primary Immunodeficiency Discoveries (RAPID)?
To fund innovative research in gene therapy and other novel approaches for Primary Immunodeficiency Disorders, while supporting genetic testing, mitochondrial health, and education to improve the lives of affected children and families.
What type of organization is Research Alliance for Primary Immunodeficiency Discoveries (RAPID)?
Research Alliance for Primary Immunodeficiency Discoveries (RAPID) is a Foundation.
What is Research Alliance for Primary Immunodeficiency Discoveries (RAPID)'s official website?
Research Alliance for Primary Immunodeficiency Discoveries (RAPID)'s official website is https://rapidfoundation.org/.
What else should I know about Research Alliance for Primary Immunodeficiency Discoveries (RAPID)?
Rôle de RAPID dans l'écosystème du financement
RAPID est une fondation de recherche dédiée au financement de la recherche sur les immunodéficiences primaires (PID) et les maladies génétiques rares. L'organisation collabore avec des laboratoires de recherche de premier plan, notamment le programme de thérapie génique de l'UCLA sous la direction du Dr Donald Kohn, pour développer des traitements innovants par édition génique.
Domaines de financement
- Thérapie génique utilisant la technologie Prime Editing
- Tests géniques pour le diagnostic des PID
- Recherche sur la santé mitochondriale
- Optimisation circadienne et mitochondriale
- Eau appauvrie en deutérium (DDW)
- Éducation et sensibilisation aux PID
Impact et reach géographique
Basée au Canada, RAPID finance des recherches ayant un impact mondial. L'organisation soutient une personne atteinte d'IMD76 (Human FCH01 Deficiency), une immunodéficience primaire ultra-rare dont elle est le 20e cas documenté au monde et le seul en Amérique du Nord.